263 related articles for article (PubMed ID: 25442812)
1. The effects of palliative chemotherapy in metastatic colorectal cancer patients with an ECOG performance status of 3 and 4.
Crosara Teixeira M; Marques DF; Ferrari AC; Alves MF; Alex AK; Sabbaga J; Hoff PM; Riechelmann RP
Clin Colorectal Cancer; 2015 Mar; 14(1):52-7. PubMed ID: 25442812
[TBL] [Abstract][Full Text] [Related]
2. Palliative chemotherapy for gastroesophageal cancer in old and very old patients: A retrospective cohort study at the National Center for Tumor Diseases, Heidelberg.
Berger AK; Zschaebitz S; Komander C; Jäger D; Haag GM
World J Gastroenterol; 2015 Apr; 21(16):4911-8. PubMed ID: 25945004
[TBL] [Abstract][Full Text] [Related]
3. Impact of palliative chemotherapy and best supportive care on overall survival and length of hospitalization in patients with incurable Cancer: a 4-year single institution experience in Japan.
Murakawa Y; Sakayori M; Otsuka K
BMC Palliat Care; 2019 Jun; 18(1):45. PubMed ID: 31159782
[TBL] [Abstract][Full Text] [Related]
4. Palliative chemotherapy in elderly patients with common metastatic malignancies: A Hellenic Cooperative Oncology Group registry analysis of management, outcome and clinical benefit predictors.
Pentheroudakis G; Fountzilas G; Kalofonos HP; Golfinopoulos V; Aravantinos G; Bafaloukos D; Papakostas P; Pectasides D; Christodoulou C; Syrigos K; Economopoulos T; Pavlidis N;
Crit Rev Oncol Hematol; 2008 Jun; 66(3):237-47. PubMed ID: 18243010
[TBL] [Abstract][Full Text] [Related]
5. Inpatient palliative chemotherapy is associated with high mortality and aggressive end-of-life care in patients with advanced solid tumors and poor performance status.
Fiorin de Vasconcellos V; Rcc Bonadio R; Avanço G; Negrão MV; Pimenta Riechelmann R
BMC Palliat Care; 2019 May; 18(1):42. PubMed ID: 31109330
[TBL] [Abstract][Full Text] [Related]
6. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial.
Heinemann V; von Weikersthal LF; Decker T; Kiani A; Vehling-Kaiser U; Al-Batran SE; Heintges T; Lerchenmüller C; Kahl C; Seipelt G; Kullmann F; Stauch M; Scheithauer W; Hielscher J; Scholz M; Müller S; Link H; Niederle N; Rost A; Höffkes HG; Moehler M; Lindig RU; Modest DP; Rossius L; Kirchner T; Jung A; Stintzing S
Lancet Oncol; 2014 Sep; 15(10):1065-75. PubMed ID: 25088940
[TBL] [Abstract][Full Text] [Related]
7. Palliative care in poor-performance status small cell lung cancer patients: is there a mandatory role for chemotherapy?
Baldotto CS; Cronemberger EH; de Biasi P; Zamboni M; Sousa A; Zukin M; Small IA; Ferreira CG
Support Care Cancer; 2012 Nov; 20(11):2721-7. PubMed ID: 22322592
[TBL] [Abstract][Full Text] [Related]
8. Performance status and cytoreductive nephrectomy: redefining management in patients with poor performance.
Shuch B; La Rochelle JC; Wu J; Klatte T; Riggs SB; Kabbinavar F; Belldegrun AS; Pantuck AJ
Cancer; 2008 Sep; 113(6):1324-31. PubMed ID: 18661529
[TBL] [Abstract][Full Text] [Related]
9. [Correlation analysis between abundance of K-ras mutation in plasma free DNA and its correlation with clinical outcome and prognosis in patients with metastatic colorectal cancer].
Bai YQ; Liu XJ; Wang Y; Ge FJ; Zhao CH; Fu YL; Lin L; Xu JM
Zhonghua Zhong Liu Za Zhi; 2013 Sep; 35(9):666-71. PubMed ID: 24332053
[TBL] [Abstract][Full Text] [Related]
10. Comparison of an inflammation-based prognostic score (GPS) with performance status (ECOG-ps) in patients receiving palliative chemotherapy for gastroesophageal cancer.
Crumley AB; Stuart RC; McKernan M; McDonald AC; McMillan DC
J Gastroenterol Hepatol; 2008 Aug; 23(8 Pt 2):e325-9. PubMed ID: 17645468
[TBL] [Abstract][Full Text] [Related]
11. Oxaliplatin-based chemotherapy in the treatment of elderly patients with metastatic colorectal cancer (CRC).
Berretta M; Zanet E; Nasti G; Lleshi A; Frustaci S; Fiorica F; Bearz A; Talamini R; Lestuzzi C; Lazzarini R; Fisichella R; Cannizzaro R; Iaffaioli RV; Berretta S; Tirelli U
Arch Gerontol Geriatr; 2012; 55(2):271-5. PubMed ID: 21937127
[TBL] [Abstract][Full Text] [Related]
12. Clinical significance of primary tumor resection in colorectal cancer patients with synchronous unresectable metastasis.
Kim MS; Chung M; Ahn JB; Kim CW; Cho MS; Shin SJ; Baek SJ; Hur H; Min BS; Baik SH; Kim NK
J Surg Oncol; 2014 Aug; 110(2):214-21. PubMed ID: 24668581
[TBL] [Abstract][Full Text] [Related]
13. A retrospective cohort study of metastatic colorectal cancer patients treated with oxaliplatin-based chemotherapy, with an exploratory analysis of changing serum carcinoembryonic antigen levels.
Ng SL; Burns WI; Snyder RD; Newnham GM; McLachlan SA; Liew D; Dowling AJ
Asia Pac J Clin Oncol; 2012 Jun; 8(2):172-9. PubMed ID: 22524576
[TBL] [Abstract][Full Text] [Related]
14. Clinical outcomes of leptomeningeal metastasis in patients with non-small cell lung cancer in the modern chemotherapy era.
Park JH; Kim YJ; Lee JO; Lee KW; Kim JH; Bang SM; Chung JH; Kim JS; Lee JS
Lung Cancer; 2012 Jun; 76(3):387-92. PubMed ID: 22186628
[TBL] [Abstract][Full Text] [Related]
15. ECOG performance score 0 versus 1: impact on efficacy and safety of first-line 5-FU-based chemotherapy among patients with metastatic colorectal cancer included in five randomized trials.
Abdel-Rahman O
Int J Colorectal Dis; 2019 Dec; 34(12):2143-2150. PubMed ID: 31732876
[TBL] [Abstract][Full Text] [Related]
16. Capecitabine and oxaliplatin (XELOX) as first-line treatment for patients with metastatic colorectal cancer.
Karacetin D; Yalcin B; Okten B; Ozturk S; Maral O; Incekara O
J BUON; 2009; 14(4):605-8. PubMed ID: 20148449
[TBL] [Abstract][Full Text] [Related]
17. Comparative analysis of comorbidity and performance indices for prediction of oncological outcomes in patients with upper tract urothelial carcinoma who were treated with radical nephroureterectomy.
Aziz A; Fritsche HM; Gakis G; Kluth LA; Hassan Fa; Engel O; Dahlem R; Otto W; Gierth M; Denzinger S; Schwentner C; Stenzl A; Shariat SF; Fisch M; Burger M; Rink M
Urol Oncol; 2014 Nov; 32(8):1141-50. PubMed ID: 24856977
[TBL] [Abstract][Full Text] [Related]
18. Phase II trial of FOLFOX6, bevacizumab, and cetuximab in the first-line treatment of metastatic colorectal cancer.
Spigel DR; Greco FA; Waterhouse D; Shipley D; Lane CM; Vazquez ER; Clark BL; Infante JR; Bendell JC; Burris HA; Hainsworth JD
Clin Adv Hematol Oncol; 2010 Jul; 8(7):480-5, 498. PubMed ID: 20864916
[TBL] [Abstract][Full Text] [Related]
19. Patterns of Use, Safety, and Effectiveness of Targeted Therapies in First-Line Treatment of Metastatic Colorectal Cancer According to Age: The STROMBOLI Cohort Study.
Gouverneur A; Coutureau J; Jové J; Rouyer M; Grelaud A; Duc S; Gérard S; Smith D; Ravaud A; Droz C; Bernard MA; Lassalle R; Forrier-Réglat A; Noize P;
Clin Colorectal Cancer; 2019 Mar; 18(1):e150-e162. PubMed ID: 30630730
[TBL] [Abstract][Full Text] [Related]
20. Treatment-related toxicity and supportive care in metastatic colorectal cancer.
Zafar SY; Marcello JE; Wheeler JL; Rowe KL; Morse MA; Herndon JE; Abernethy AP
J Support Oncol; 2010; 8(1):15-20. PubMed ID: 20235419
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]